Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis

• Type: Article in International Scientific Journal
• Date: 2010

Authors

Rui Pinto (Author) FMUP; Tiago Lopes (Author) FMUP; Bárbara Garrido (Author) FMUP; Andre Silva (Author) FMUP; Joao Silva (Author) FMUP; Carlos Silva (Author) FMUP; Célia Cruz (Author) FMUP; Francisco Cruz (Author) FMUP; Paulo Oliveira (Author) FMUP

Journal

Title: European Urology

Vol. 58 No. 3

Pages: 360-365

ISSN: 0302-2838

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 136 Citations

Scopus - 155 Citations

Pubmed / Medline

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

CORDIS: Health sciences > Medical sciences > Medicine > Urology

Other information

Authenticus ID: P-003-3CA

DOI: 10.1016/j.eururo.2010.02.031

Abstract (EN): Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease without an effective treatment, characterized by pain during bladder filling. Most nociceptive bladder afferents course in the trigone. Objective: To evaluate efficacy and tolerability of trigonal injection of botulinum toxin A (BoNTA) in patients with BPS/IC. Urine concentration of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) were also evaluated. Design, setting, and participants: Women with refractory BPS/IC were included in an open, exploratory study. Intervention: Under sedation, 100 U of BoNTA (Botox) were injected in 10 trigonal sites (10 U per 1 ml saline). Retreatment was allowed 3 mo after injection. Measurements: Pain, urinary frequency, O'Leary-Sant score (OSS), quality of life, (QoL), and urodynamic testing at 1 and 3 mo and every 3 mo thereafter. Urine NGF and BDNF were assessed at the same points. Patients who were retreated were evaluated every 3 mo. Results and limitations: All patients reported subjective improvement at 1- and 3-mo follow-up. Pain, daytime and nighttime voiding frequency, OSS, and QoL improved significantly. Bladder volume to first pain and maximal cystometric capacity more than doubled. Treatment remained effective in >50% of the patients for 9 mo. Retreatment was also effective in all cases, with similar duration. A significant, transient reduction in urinary NGF and BDNF was observed. No cases of voiding dysfunction occurred. The low number of patients and the lack of a placebo arm are obvious limitations of this study. Conclusions: Trigonal injection of BoNTA is a safe and effective treatment for refractory BPS/IC.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6